RAYMOND JAMES & ASSOCIATES - NEKTAR THERAPEUTICS ownership

NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 155 filers reported holding NEKTAR THERAPEUTICS in Q1 2015. The put-call ratio across all filers is 0.53 and the average weighting 0.1%.

Quarter-by-quarter ownership
RAYMOND JAMES & ASSOCIATES ownership history of NEKTAR THERAPEUTICS
ValueSharesWeighting
Q3 2022$32,000
-45.8%
10,001
-35.8%
0.00%
Q2 2022$59,000
-39.2%
15,579
-13.4%
0.00%
Q1 2022$97,000
-74.8%
17,999
-36.9%
0.00%
Q4 2021$385,000
-32.1%
28,516
-9.7%
0.00%
-100.0%
Q3 2021$567,000
+19.6%
31,576
+14.3%
0.00%
Q2 2021$474,000
-18.4%
27,615
-4.9%
0.00%
-100.0%
Q1 2021$581,000
+27.7%
29,050
+8.5%
0.00%
Q4 2020$455,000
+2.9%
26,785
+0.5%
0.00%
-100.0%
Q3 2020$442,000
-29.5%
26,665
-1.5%
0.00%0.0%
Q2 2020$627,000
+36.9%
27,067
+5.5%
0.00%0.0%
Q1 2020$458,000
-18.8%
25,652
-1.8%
0.00%0.0%
Q4 2019$564,000
+26.2%
26,135
+6.5%
0.00%0.0%
Q3 2019$447,000
-79.1%
24,532
-59.2%
0.00%
-66.7%
Q2 2019$2,142,000
+48.5%
60,189
+40.2%
0.00%
+50.0%
Q1 2019$1,442,000
+4.9%
42,919
+2.6%
0.00%0.0%
Q4 2018$1,375,000
-61.0%
41,825
-27.8%
0.00%
-60.0%
Q3 2018$3,530,000
+6.7%
57,908
-14.5%
0.01%
-16.7%
Q2 2018$3,308,000
-66.2%
67,746
-26.5%
0.01%
-66.7%
Q1 2018$9,792,000
+19.6%
92,148
-43.7%
0.02%
+20.0%
Q4 2017$8,190,000
+166.8%
163,617
+27.9%
0.02%
+150.0%
Q3 2017$3,070,000
+23.7%
127,900
+0.7%
0.01%
+20.0%
Q2 2017$2,482,000
-9.4%
126,950
+8.7%
0.01%
-16.7%
Q1 2017$2,740,000
+51.0%
116,760
-21.1%
0.01%
+20.0%
Q4 2016$1,815,000
-5.6%
147,960
+32.2%
0.01%0.0%
Q3 2016$1,923,000
+59.5%
111,904
+32.0%
0.01%
+25.0%
Q2 2016$1,206,000
+6.1%
84,761
+2.5%
0.00%0.0%
Q1 2016$1,137,000
-16.0%
82,696
+3.0%
0.00%
-20.0%
Q4 2015$1,353,000
+60.1%
80,280
+4.2%
0.01%
+66.7%
Q3 2015$845,000
-10.5%
77,060
+2.1%
0.00%
-25.0%
Q2 2015$944,000
+34.1%
75,460
+17.9%
0.00%
+33.3%
Q1 2015$704,000
+96.6%
64,010
+177.1%
0.00%
+50.0%
Q4 2014$358,00023,1000.00%
Other shareholders
NEKTAR THERAPEUTICS shareholders Q1 2015
NameSharesValueWeighting ↓
Strong Tower Advisory Services 404,972$6,913,0004.02%
GREAT POINT PARTNERS LLC 504,691$9,064,0002.11%
Camber Capital Management LP 3,750,000$67,350,0002.07%
ACT CAPITAL MANAGEMENT, LLC 161,500$2,901,0001.50%
Rhenman & Partners Asset Management AB 950,000$17,062,0001.20%
MAVERICK CAPITAL LTD 5,838,426$104,858,0001.06%
Birchview Capital, LP 72,000$1,293,0000.88%
Bellevue Group AG 4,594,656$82,519,0000.84%
CM Management, LLC 50,000$898,0000.67%
Duquesne Family Office 1,000,000$17,960,0000.58%
View complete list of NEKTAR THERAPEUTICS shareholders